GMP Warnings Follow Thin Corrective Action Evidence, Reliance On Contract Manufacturers
This article was originally published in The Rose Sheet
Executive Summary
FDA warning letters to VitaPurity and Morhaim Pharmalab remind the supplement firms they can’t rely on contract manufacturers and suppliers to meet FDA’s GMP practices, and that statements of corrective actions without proof are inadequate.
You may also be interested in...
Total Nutrition Latest Own-Label Supplement Marketer Warned On GMP Violations
FDA warns Total Nutrition that it violated numerous supplement GMPs and reminds the firm that own-label marketers are ultimately responsible for ensuring their contract manufacturers’ compliance. The agency also said numerous online claims rendered the products as unapproved drugs.
PharmaTech Recalls Highlight Supplement GMP Diligence For Marketers – CRN
PharmaTech customers recall liquid supplements, including products indicated for children, after CDC informs FDA that an antibiotic-resistant pathogen was found in a PharmaTech Rx drug. CRN says the recall should remind supplement firms about tracking supply chains and auditing contract manufacturers.
Supplement GMP Warnings Pass 2015 Total, Own-Labeler Problems Climb
Three supplement GMP warning letters FDA posted on Oct. 25 push the year's total to 26, up from 22 in 2015. The overall total of FDA warnings in the supplement sector so far in 2016 is 60.